Noninvasive Urinary Metabonomic Diagnosis of Human Bladder Cancer

作者：Pasikanti Kishore Kumar; Esuvaranathan Kesavan; Ho Paul C; Mahendran Ratha; Kamaraj Revathi; Wu Qing Hui; Chiong Edmund; Chan Eric Chun Yong^*

来源：Journal of Proteome Research, 2010, 9(6): 2988-2995.

DOI：10.1021/pr901173v

• bladder cancer
• gas chromatography mass spectrometry
• metabolomics
• metabonomics
• metabolic profiling
• diagnosis

Cystoscopy is considered the gold standard for the clinical diagnosis of human bladder cancer (BC). As cystoscopy is expensive and invasive, it may compromise patients' compliance and account for the failure in detecting recurrent BC in some patients. In this paper, we investigated the role of urinary metabonomics in the diagnosis of human BC. Gas chromatography/time-of-flight mass spectrometry was applied for the urinary metabolic profiling of 24 BC patients and 51 non-BC controls. The acquired data were analyzed using multivariate principal component analysis followed by orthogonal partial least-squares discriminant analysis (OPLS-DA). Model validity was verified using permutation tests and receiver operating characteristic (ROC) analysis. BC patients were clearly distinguished from non-BC subjects based on their global urinary metabolic profiles (OPLS-DA, 4 latent variables, R(2)X = 0.420, R(2)Y = 0.912 and Q(2) (cumulative) = 0.245; ROC AUC of 0.90; 15 marker metabolites). One-hundred percent sensitivity in detecting BC was observed using urinary metabonomics versus 33% sensitivity achieved by urinary cytology. Additionally, urinary metabonomics exhibited potential in the staging and grading of bladder tumors. In summary, urinary metabonomics is amenable for the noninvasive diagnosis of human BC.

• 出版日期2010-6